GeneDx (NASDAQ:WGS) Stock Price Up 6.5% on Earnings Beat

GeneDx Holdings Corp. (NASDAQ:WGS) traded up 6.5% during trading on Monday following a stronger than expected earnings report. The stock traded as high as $86.84 and last traded at $87.3630. 794,733 shares changed hands during trading, an increase of 9% from the average session volume of 727,435 shares. The stock had previously closed at $82.06.

The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The firm had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Q4 results slightly beat expectations: GAAP EPS was $0.14 vs. a $0.11 consensus and revenue was $120.99M vs. ~$120.8M consensus — a classic earnings beat that likely drove buying interest. GeneDx Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company reaffirmed full‑year 2026 guidance in its press release, which removes some uncertainty about near‑term expectations and supports the share move. GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
• Positive Sentiment: Trading volume jumped well above average on the print, indicating strong investor attention and likely contributing to the price rise. (See company release and MarketBeat summary for volume/context.) MarketBeat: GeneDx Earnings Summary & Call
• Neutral Sentiment: Full earnings call transcripts and slides are posted (useful for management commentary on volumes, margins and product mix). Read the call for color on drivers and execution. GeneDx (WGS) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Several outlets labeled the print “mixed” (some headlines suggested an earnings miss), which can create short‑term headline volatility despite the underlying beat. Investors should read the release/call rather than rely on summary headlines. GeneDx delivers mixed Q4 results
• Negative Sentiment: Profitability and valuation remain concerns: net margin was only ~0.5% for the quarter and the shares trade at a very high P/E, which leaves the stock vulnerable if growth or margin improvement disappoints. MarketBeat: WGS Profile & Valuation

Analyst Ratings Changes

WGS has been the topic of a number of research analyst reports. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research report on Monday. Canaccord Genuity Group increased their price target on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price objective for the company in a research report on Monday, February 9th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $156.43.

Insider Buying and Selling

In other news, COO Bryan Dechairo sold 5,961 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Feeley sold 317 shares of the firm’s stock in a transaction on Thursday, January 29th. The shares were sold at an average price of $93.99, for a total transaction of $29,794.83. Following the sale, the chief financial officer owned 9,168 shares in the company, valued at $861,700.32. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 30,961 shares of company stock valued at $3,933,831. 29.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GeneDx

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in GeneDx by 4.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after acquiring an additional 52,322 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of GeneDx by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after purchasing an additional 18,647 shares during the period. Franklin Resources Inc. boosted its holdings in shares of GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the period. Westfield Capital Management Co. LP increased its position in shares of GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after purchasing an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. lifted its position in GeneDx by 59.2% in the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after buying an additional 292,394 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Price Performance

The firm has a market cap of $2.52 billion, a P/E ratio of 967.56 and a beta of 2.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The stock’s 50-day simple moving average is $111.12 and its two-hundred day simple moving average is $124.65.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.